Mirdametinib (Synonyms: PD0325901; PD325901)

Name: Mirdametinib
Brand: MedChemExpress
SKU: HY-10254G
Rating: 5.0 (1 reviews)

Cat. No.: HY-10254G: Data Sheet
SDS
Handling Instructions
FAQs
Technical Support

Mirdametinib (PD0325901) (GMP) is Mirdametinib (HY-10254) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Mirdametinib is an orally active, selective and non-ATP-competitive MEK inhibitor.

For research use only. We do not sell to patients.

Mirdametinib Chemical Structure

CAS No. : 391210-10-9

Size	Stock	Quantity
10 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	Get quote
500 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

1 Publications Citing Use of MCE Mirdametinib

•bioRxiv. 2025 Nov 12.

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All MEK Isoform Specific Products:

View All Isoforms

MEK1 MEK2 MEK5 MEK MAP2K4/MEK4 MAP2K7/MEK7

Biological Activity
Purity & Documentation
References
Customer Review

Description

Cellular Effect

Cell Line	Type	Value	Description	References
A-431	IC₅₀	0.038 3 Compound: PD-0325901	Inhibition of MEK/ERK signaling pathway in EGF-stimulated human A431 cells transfected with COT siRNA assessed as reduction in ERK1/2 phosphorylation incubated for 60 mins followed by stimulation with EGF for 10 mins by Western blot analysis Inhibition of MEK/ERK signaling pathway in EGF-stimulated human A431 cells transfected with COT siRNA assessed as reduction in ERK1/2 phosphorylation incubated for 60 mins followed by stimulation with EGF for 10 mins by Western blot analysis	[PMID: 27502541]
A-375	GI₅₀	1.28 1 Compound: 5; PD-325901	Antiproliferative activity against human A-375 cells harboring BRAF V600E mutant assessed as cell growth inhibition incubated for 72 hrs in the absence of UV irradiation by CellTiter-Glo luminescent assay Antiproliferative activity against human A-375 cells harboring BRAF V600E mutant assessed as cell growth inhibition incubated for 72 hrs in the absence of UV irradiation by CellTiter-Glo luminescent assay	[PMID: 36924668]
A-375	GI₅₀	1.37 1 Compound: 5; PD-325901	Antiproliferative activity against human A-375 cells harboring BRAF V600E mutant assessed as cell growth inhibition preincubated with compound for 1 hrs followed by UV irradiation for 1 min and measured 72 hrs post compound treatment by CellTiter-Glo lumi Antiproliferative activity against human A-375 cells harboring BRAF V600E mutant assessed as cell growth inhibition preincubated with compound for 1 hrs followed by UV irradiation for 1 min and measured 72 hrs post compound treatment by CellTiter-Glo lumi	[PMID: 36924668]
A-431	IC₅₀	<0.014 3 Compound: PD-0325901	Inhibition of MEK/ERK signaling pathway in TNFalpha-stimulated human A431 cells transfected with COT siRNA assessed as reduction in ERK1/2 phosphorylation incubated for 60 mins followed by stimulation with TNFalpha for 10 mins by Western blot analysis Inhibition of MEK/ERK signaling pathway in TNFalpha-stimulated human A431 cells transfected with COT siRNA assessed as reduction in ERK1/2 phosphorylation incubated for 60 mins followed by stimulation with TNFalpha for 10 mins by Western blot analysis	[PMID: 27502541]
A-375	GI₅₀	1.49 1 Compound: 5; PD-325901	Antiproliferative activity against human A-375 cells harboring BRAF V600E mutant assessed as cell growth inhibition preincubated with compound for 1 hrs followed by UV irradiation for 5 mins and measured 72 hrs post compound treatment by CellTiter-Glo lum Antiproliferative activity against human A-375 cells harboring BRAF V600E mutant assessed as cell growth inhibition preincubated with compound for 1 hrs followed by UV irradiation for 5 mins and measured 72 hrs post compound treatment by CellTiter-Glo lum	[PMID: 36924668]
A549	CC₅₀	>100 3 Compound: PD-0325901	Cytotoxicity against human A549 cells Cytotoxicity against human A549 cells	[PMID: 33539089]
A-375	GI₅₀	1.59 1 Compound: 5; PD-325901	Antiproliferative activity against human A-375 cells harboring BRAF V600E mutant assessed as cell growth inhibition preincubated with compound for 1 hrs followed by UV irradiation for 3 mins and measured 72 hrs post compound treatment by CellTiter-Glo lum Antiproliferative activity against human A-375 cells harboring BRAF V600E mutant assessed as cell growth inhibition preincubated with compound for 1 hrs followed by UV irradiation for 3 mins and measured 72 hrs post compound treatment by CellTiter-Glo lum	[PMID: 36924668]
COLO 205	GI₅₀	0.2 1 Compound: 4; PD0325901	Antiproliferative activity against human COLO205 cells assessed as reduction in cell growth after 3 days by WST8 assay Antiproliferative activity against human COLO205 cells assessed as reduction in cell growth after 3 days by WST8 assay	[PMID: 31730343]
UACC-257	GI₅₀	0.2 1 Compound: 4; PD0325901	Antiproliferative activity against human UACC257 cells assessed as reduction in cell growth after 3 days by MTT assay Antiproliferative activity against human UACC257 cells assessed as reduction in cell growth after 3 days by MTT assay	[PMID: 31730343]
A-375	IC₅₀	13 1 Compound: PD325901	Antiproliferative activity against human A375 cells expressing BRAF V600E mutant after 72 hrs by Cell titer-glo assay Antiproliferative activity against human A375 cells expressing BRAF V600E mutant after 72 hrs by Cell titer-glo assay	[PMID: 23474388]
A549	IC₅₀	0.06 3 Compound: PD0325901	Antiproliferative activity against human A549 cells harboring KRAS G12S mutant assessed as inhibition of cell viability after 96 hrs by Celltiter-Glo assay Antiproliferative activity against human A549 cells harboring KRAS G12S mutant assessed as inhibition of cell viability after 96 hrs by Celltiter-Glo assay	[PMID: 32305784]
A-431	IC₅₀	0.038 3 Compound: PD-0325901	Inhibition of MEK/ERK signaling pathway in EGF-stimulated human A431 cells transfected with COT siRNA assessed as reduction in ERK1/2 phosphorylation incubated for 60 mins followed by stimulation with EGF for 10 mins by Western blot analysis Inhibition of MEK/ERK signaling pathway in EGF-stimulated human A431 cells transfected with COT siRNA assessed as reduction in ERK1/2 phosphorylation incubated for 60 mins followed by stimulation with EGF for 10 mins by Western blot analysis	[PMID: 27502541]
A-431	IC₅₀	< 0.014 3 Compound: PD-0325901	Inhibition of MEK/ERK signaling pathway in TNFalpha-stimulated human A431 cells transfected with COT siRNA assessed as reduction in ERK1/2 phosphorylation incubated for 60 mins followed by stimulation with TNFalpha for 10 mins by Western blot analysis Inhibition of MEK/ERK signaling pathway in TNFalpha-stimulated human A431 cells transfected with COT siRNA assessed as reduction in ERK1/2 phosphorylation incubated for 60 mins followed by stimulation with TNFalpha for 10 mins by Western blot analysis	[PMID: 27502541]
A-375	GI₅₀	1.28 1 Compound: 5; PD-325901	Antiproliferative activity against human A-375 cells harboring BRAF V600E mutant assessed as cell growth inhibition incubated for 72 hrs in the absence of UV irradiation by CellTiter-Glo luminescent assay Antiproliferative activity against human A-375 cells harboring BRAF V600E mutant assessed as cell growth inhibition incubated for 72 hrs in the absence of UV irradiation by CellTiter-Glo luminescent assay	[PMID: 36924668]
A549	CC₅₀	> 100 3 Compound: PD-0325901	Cytotoxicity against human A549 cells Cytotoxicity against human A549 cells	[PMID: 33539089]
A-375	GI₅₀	1.37 1 Compound: 5; PD-325901	Antiproliferative activity against human A-375 cells harboring BRAF V600E mutant assessed as cell growth inhibition preincubated with compound for 1 hrs followed by UV irradiation for 1 min and measured 72 hrs post compound treatment by CellTiter-Glo lumi Antiproliferative activity against human A-375 cells harboring BRAF V600E mutant assessed as cell growth inhibition preincubated with compound for 1 hrs followed by UV irradiation for 1 min and measured 72 hrs post compound treatment by CellTiter-Glo lumi	[PMID: 36924668]
A549	GI₅₀	10.6 1 Compound: 5; PD-325901	Antiproliferative activity against human A549 cells harboring KRas G13S mutant assessed as cell growth inhibition preincubated with compound for 1 hrs followed by UV irradiation for 5 mins and measured 72 hrs post compound treatment by CellTiter-Glo lumin Antiproliferative activity against human A549 cells harboring KRas G13S mutant assessed as cell growth inhibition preincubated with compound for 1 hrs followed by UV irradiation for 5 mins and measured 72 hrs post compound treatment by CellTiter-Glo lumin	[PMID: 36924668]
A-375	GI₅₀	1.49 1 Compound: 5; PD-325901	Antiproliferative activity against human A-375 cells harboring BRAF V600E mutant assessed as cell growth inhibition preincubated with compound for 1 hrs followed by UV irradiation for 5 mins and measured 72 hrs post compound treatment by CellTiter-Glo lum Antiproliferative activity against human A-375 cells harboring BRAF V600E mutant assessed as cell growth inhibition preincubated with compound for 1 hrs followed by UV irradiation for 5 mins and measured 72 hrs post compound treatment by CellTiter-Glo lum	[PMID: 36924668]
A-375	GI₅₀	1.59 1 Compound: 5; PD-325901	Antiproliferative activity against human A-375 cells harboring BRAF V600E mutant assessed as cell growth inhibition preincubated with compound for 1 hrs followed by UV irradiation for 3 mins and measured 72 hrs post compound treatment by CellTiter-Glo lum Antiproliferative activity against human A-375 cells harboring BRAF V600E mutant assessed as cell growth inhibition preincubated with compound for 1 hrs followed by UV irradiation for 3 mins and measured 72 hrs post compound treatment by CellTiter-Glo lum	[PMID: 36924668]
A549	GI₅₀	4.94 1 Compound: 5; PD-325901	Antiproliferative activity against human A549 cells harboring KRAS G13S mutant assessed as cell growth inhibition incubated for 72 hrs in the absence of UV irradiation by CellTiter-Glo luminescent assay Antiproliferative activity against human A549 cells harboring KRAS G13S mutant assessed as cell growth inhibition incubated for 72 hrs in the absence of UV irradiation by CellTiter-Glo luminescent assay	[PMID: 36924668]
A549	IC₅₀	0.06 3 Compound: PD0325901	Antiproliferative activity against human A549 cells harboring KRAS G12S mutant assessed as inhibition of cell viability after 96 hrs by Celltiter-Glo assay Antiproliferative activity against human A549 cells harboring KRAS G12S mutant assessed as inhibition of cell viability after 96 hrs by Celltiter-Glo assay	[PMID: 32305784]
SK-MEL-28	GI₅₀	2.9 1 Compound: 4; PD0325901	Antiproliferative activity against human SK-MEL-28 cells assessed as reduction in cell growth after 3 days by MTT assay Antiproliferative activity against human SK-MEL-28 cells assessed as reduction in cell growth after 3 days by MTT assay	[PMID: 31730343]
A549	IC₅₀	166 1 Compound: PD325901	Antiproliferative activity against human A549 cells Antiproliferative activity against human A549 cells	[PMID: 23474388]
HT-29	GI₅₀	3.1 1 Compound: 4; PD0325901	Antiproliferative activity against human HT-29 cells assessed as reduction in cell growth after 3 days by MTT assay Antiproliferative activity against human HT-29 cells assessed as reduction in cell growth after 3 days by MTT assay	[PMID: 31730343]
A549	IC₅₀	166 1 Compound: PD325901	Antiproliferative activity against human A549 cells harboring K-Ras mutation Antiproliferative activity against human A549 cells harboring K-Ras mutation	[PMID: 26611920]
A549	GI₅₀	4.94 1 Compound: 5; PD-325901	Antiproliferative activity against human A549 cells harboring KRAS G13S mutant assessed as cell growth inhibition incubated for 72 hrs in the absence of UV irradiation by CellTiter-Glo luminescent assay Antiproliferative activity against human A549 cells harboring KRAS G13S mutant assessed as cell growth inhibition incubated for 72 hrs in the absence of UV irradiation by CellTiter-Glo luminescent assay	[PMID: 36924668]
COLO 205	GI₅₀	0.2 1 Compound: 4; PD0325901	Antiproliferative activity against human COLO205 cells assessed as reduction in cell growth after 3 days by WST8 assay Antiproliferative activity against human COLO205 cells assessed as reduction in cell growth after 3 days by WST8 assay	[PMID: 31730343]
COLO 205	IC₅₀	5 1 Compound: PD325901	Antiproliferative activity against human COLO205 cells harboring BRAF mutation Antiproliferative activity against human COLO205 cells harboring BRAF mutation	[PMID: 26611920]
COLO 205	IC₅₀	5 1 Compound: PD325901	Antiproliferative activity against human COLO205 cells harboring BRAF mutation Antiproliferative activity against human COLO205 cells harboring BRAF mutation	[PMID: 26611920]
HepG2	IC₅₀	5 1 Compound: PD325901	Antiproliferative activity against human HepG2 cells harboring N-Ras mutation Antiproliferative activity against human HepG2 cells harboring N-Ras mutation	[PMID: 26611920]
HCT-116	IC₅₀	0.09 3 Compound: PD0325901	Antiproliferative activity against human HCT116 cells harboring KRAS G13D mutant assessed as inhibition of cell viability after 96 hrs by Celltiter-Glo assay Antiproliferative activity against human HCT116 cells harboring KRAS G13D mutant assessed as inhibition of cell viability after 96 hrs by Celltiter-Glo assay	[PMID: 32305784]
A549	GI₅₀	10.6 1 Compound: 5; PD-325901	Antiproliferative activity against human A549 cells harboring KRas G13S mutant assessed as cell growth inhibition preincubated with compound for 1 hrs followed by UV irradiation for 5 mins and measured 72 hrs post compound treatment by CellTiter-Glo lumin Antiproliferative activity against human A549 cells harboring KRas G13S mutant assessed as cell growth inhibition preincubated with compound for 1 hrs followed by UV irradiation for 5 mins and measured 72 hrs post compound treatment by CellTiter-Glo lumin	[PMID: 36924668]
HCT-116	GI₅₀	44.7 1 Compound: 5; PD-325901	Antiproliferative activity against human HCT-116 cells harboring KRAS G13D mutant assessed as cell growth inhibition incubated for 72 hrs in the absence of UV irradiation by CellTiter-Glo luminescent assay Antiproliferative activity against human HCT-116 cells harboring KRAS G13D mutant assessed as cell growth inhibition incubated for 72 hrs in the absence of UV irradiation by CellTiter-Glo luminescent assay	[PMID: 36924668]
HCT-116	GI₅₀	52.5 1 Compound: 5; PD-325901	Antiproliferative activity against human HCT-116 cells harboring KRAS G13D mutant assessed as cell growth inhibition preincubated with compound for 1 hrs followed by UV irradiation for 5 mins and measured 72 hrs post compound treatment by CellTiter-Glo lu Antiproliferative activity against human HCT-116 cells harboring KRAS G13D mutant assessed as cell growth inhibition preincubated with compound for 1 hrs followed by UV irradiation for 5 mins and measured 72 hrs post compound treatment by CellTiter-Glo lu	[PMID: 36924668]
A-375	IC₅₀	13 1 Compound: PD325901	Antiproliferative activity against human A375 cells expressing BRAF V600E mutant after 72 hrs by Cell titer-glo assay Antiproliferative activity against human A375 cells expressing BRAF V600E mutant after 72 hrs by Cell titer-glo assay	[PMID: 23474388]
HCT-116	IC₅₀	0.09 3 Compound: PD0325901	Antiproliferative activity against human HCT116 cells harboring KRAS G13D mutant assessed as inhibition of cell viability after 96 hrs by Celltiter-Glo assay Antiproliferative activity against human HCT116 cells harboring KRAS G13D mutant assessed as inhibition of cell viability after 96 hrs by Celltiter-Glo assay	[PMID: 32305784]
HEK-293T	GI₅₀	>10 3 Compound: 5; PD-325901	Cytotoxicity against HEK293T cells assessed as cell growth inhibition incubated for 72 hrs by CellTiter-Glo luminescent assay Cytotoxicity against HEK293T cells assessed as cell growth inhibition incubated for 72 hrs by CellTiter-Glo luminescent assay	[PMID: 36924668]
HCT-116	IC₅₀	185 1 Compound: PD325901	Antiproliferative activity against human HCT116 cells harboring K-Ras G13D mutation Antiproliferative activity against human HCT116 cells harboring K-Ras G13D mutation	[PMID: 26611920]
MIA PaCa-2	IC₅₀	17 1 Compound: PD325901	Antiproliferative activity against human MIAPaCa2 cells Antiproliferative activity against human MIAPaCa2 cells	[PMID: 23474388]
HCT-116	IC₅₀	194 1 Compound: PD325901	Antiproliferative activity against human HCT116 cells expressing KRAS G13D mutant Antiproliferative activity against human HCT116 cells expressing KRAS G13D mutant	[PMID: 23474388]
HL-60	IC₅₀	0.0013 3 Compound: PD0325901	Antiproliferative activity against human HL60 cells harboring NRAS K61L mutant assessed as inhibition of cell viability after 96 hrs by Celltiter-Glo assay Antiproliferative activity against human HL60 cells harboring NRAS K61L mutant assessed as inhibition of cell viability after 96 hrs by Celltiter-Glo assay	[PMID: 32305784]
HCT-116	GI₅₀	44.7 1 Compound: 5; PD-325901	Antiproliferative activity against human HCT-116 cells harboring KRAS G13D mutant assessed as cell growth inhibition incubated for 72 hrs in the absence of UV irradiation by CellTiter-Glo luminescent assay Antiproliferative activity against human HCT-116 cells harboring KRAS G13D mutant assessed as cell growth inhibition incubated for 72 hrs in the absence of UV irradiation by CellTiter-Glo luminescent assay	[PMID: 36924668]
HEK-293T	GI₅₀	> 10000 1 Compound: 5; PD-325901	Cytotoxicity against HEK293T cells assessed as cell growth inhibition incubated for 72 hrs by CellTiter-Glo luminescent assay Cytotoxicity against HEK293T cells assessed as cell growth inhibition incubated for 72 hrs by CellTiter-Glo luminescent assay	[PMID: 36924668]
HL-60	IC₅₀	0.0013 3 Compound: PD0325901	Antiproliferative activity against human HL60 cells harboring NRAS K61L mutant assessed as inhibition of cell viability after 96 hrs by Celltiter-Glo assay Antiproliferative activity against human HL60 cells harboring NRAS K61L mutant assessed as inhibition of cell viability after 96 hrs by Celltiter-Glo assay	[PMID: 32305784]
HCT-116	GI₅₀	52.5 1 Compound: 5; PD-325901	Antiproliferative activity against human HCT-116 cells harboring KRAS G13D mutant assessed as cell growth inhibition preincubated with compound for 1 hrs followed by UV irradiation for 5 mins and measured 72 hrs post compound treatment by CellTiter-Glo lu Antiproliferative activity against human HCT-116 cells harboring KRAS G13D mutant assessed as cell growth inhibition preincubated with compound for 1 hrs followed by UV irradiation for 5 mins and measured 72 hrs post compound treatment by CellTiter-Glo lu	[PMID: 36924668]
HT-29	GI₅₀	3.1 1 Compound: 4; PD0325901	Antiproliferative activity against human HT-29 cells assessed as reduction in cell growth after 3 days by MTT assay Antiproliferative activity against human HT-29 cells assessed as reduction in cell growth after 3 days by MTT assay	[PMID: 31730343]
MDA-MB-231	GI₅₀	1 3 Compound: PD-0325901	Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs by CellTiter-Glo luminescence assay Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs by CellTiter-Glo luminescence assay	[PMID: 30802730]
HepG2	IC₅₀	5 1 Compound: PD325901	Antiproliferative activity against human HepG2 cells harboring N-Ras mutation Antiproliferative activity against human HepG2 cells harboring N-Ras mutation	[PMID: 26611920]
MDA-MB-231	IC₅₀	0.082 3 Compound: PD0325901	Antiproliferative activity against human MDA-MB-231 cells harboring KRAS G13D/BRAF G464V mutant assessed as inhibition of cell viability after 96 hrs by Celltiter-Glo assay Antiproliferative activity against human MDA-MB-231 cells harboring KRAS G13D/BRAF G464V mutant assessed as inhibition of cell viability after 96 hrs by Celltiter-Glo assay	[PMID: 32305784]
LoVo	IC₅₀	128 1 Compound: PD325901	Antiproliferative activity against human LoVo cells Antiproliferative activity against human LoVo cells	[PMID: 23474388]
A549	IC₅₀	166 1 Compound: PD325901	Antiproliferative activity against human A549 cells Antiproliferative activity against human A549 cells	[PMID: 23474388]
A549	IC₅₀	166 1 Compound: PD325901	Antiproliferative activity against human A549 cells harboring K-Ras mutation Antiproliferative activity against human A549 cells harboring K-Ras mutation	[PMID: 26611920]
LoVo	IC₅₀	128 1 Compound: PD325901	Antiproliferative activity against human LoVo cells Antiproliferative activity against human LoVo cells	[PMID: 23474388]
MCF7	IC₅₀	9550 1 Compound: PD325901	Antiproliferative activity against human MCF7 cells Antiproliferative activity against human MCF7 cells	[PMID: 26611920]
HCT-116	IC₅₀	185 1 Compound: PD325901	Antiproliferative activity against human HCT116 cells harboring K-Ras G13D mutation Antiproliferative activity against human HCT116 cells harboring K-Ras G13D mutation	[PMID: 26611920]
MDA-MB-231	GI₅₀	1 3 Compound: PD-0325901	Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs by CellTiter-Glo luminescence assay Antiproliferative activity against human MDA-MB-231 cells incubated for 72 hrs by CellTiter-Glo luminescence assay	[PMID: 30802730]
HCT-116	IC₅₀	194 1 Compound: PD325901	Antiproliferative activity against human HCT116 cells expressing KRAS G13D mutant Antiproliferative activity against human HCT116 cells expressing KRAS G13D mutant	[PMID: 23474388]
MDA-MB-231	IC₅₀	0.082 3 Compound: PD0325901	Antiproliferative activity against human MDA-MB-231 cells harboring KRAS G13D/BRAF G464V mutant assessed as inhibition of cell viability after 96 hrs by Celltiter-Glo assay Antiproliferative activity against human MDA-MB-231 cells harboring KRAS G13D/BRAF G464V mutant assessed as inhibition of cell viability after 96 hrs by Celltiter-Glo assay	[PMID: 32305784]
SU-DHL-1	GI₅₀	350 1 Compound: 1; PD0325901	Antiproliferative activity against human SU-DHL-1 cells incubated for 3 days by WST8 assay Antiproliferative activity against human SU-DHL-1 cells incubated for 3 days by WST8 assay	[PMID: 33284613]
Sf21	IC₅₀	>25 3 Compound: PD-0325901	Inhibition of human COT (66 to 395 residues) expressed in Sf21 cells using 5-Fluo-Ahx-AGAGSGQLIDSNleANSFVGTR-NH2 as substrate after 60 mins by caliper microfluidic mobility shift assay Inhibition of human COT (66 to 395 residues) expressed in Sf21 cells using 5-Fluo-Ahx-AGAGSGQLIDSNleANSFVGTR-NH2 as substrate after 60 mins by caliper microfluidic mobility shift assay	[PMID: 27502541]
MIA PaCa-2	IC₅₀	17 1 Compound: PD325901	Antiproliferative activity against human MIAPaCa2 cells Antiproliferative activity against human MIAPaCa2 cells	[PMID: 23474388]
MCF7	IC₅₀	9550 1 Compound: PD325901	Antiproliferative activity against human MCF7 cells Antiproliferative activity against human MCF7 cells	[PMID: 26611920]
SK-MEL-28	GI₅₀	2.9 1 Compound: 4; PD0325901	Antiproliferative activity against human SK-MEL-28 cells assessed as reduction in cell growth after 3 days by MTT assay Antiproliferative activity against human SK-MEL-28 cells assessed as reduction in cell growth after 3 days by MTT assay	[PMID: 31730343]
SU-DHL-1	GI₅₀	350 1 Compound: 1; PD0325901	Antiproliferative activity against human SU-DHL-1 cells incubated for 3 days by WST8 assay Antiproliferative activity against human SU-DHL-1 cells incubated for 3 days by WST8 assay	[PMID: 33284613]
Sf21	IC₅₀	> 25 3 Compound: PD-0325901	Inhibition of human COT (66 to 395 residues) expressed in Sf21 cells using 5-Fluo-Ahx-AGAGSGQLIDSNleANSFVGTR-NH2 as substrate after 60 mins by caliper microfluidic mobility shift assay Inhibition of human COT (66 to 395 residues) expressed in Sf21 cells using 5-Fluo-Ahx-AGAGSGQLIDSNleANSFVGTR-NH2 as substrate after 60 mins by caliper microfluidic mobility shift assay	[PMID: 27502541]
UACC-257	GI₅₀	0.2 1 Compound: 4; PD0325901	Antiproliferative activity against human UACC257 cells assessed as reduction in cell growth after 3 days by MTT assay Antiproliferative activity against human UACC257 cells assessed as reduction in cell growth after 3 days by MTT assay	[PMID: 31730343]

In Vitro

Mirdametinib (250 nM; 7 d) induces differentiation of cardiac PCs into vascular smooth muscle cell (VSMC)-like cells^[1].
Mirdametinib (10 μM; 4 d) induces oligodendrocyte precursor cells (OPC) to oligodendrocytes (OL) differentiation^[2].
Mirdametinib enhances embryonic stem cells (ESC) self-renewal capacity both by key regulatory genes and ES cell-specific miRNA, which in turn influences ESC self-renewal and cellular differentiation^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

482.19

Formula

C₁₆H₁₄F₃IN₂O₄

CAS No.

391210-10-9

Appearance

Solid

Color

White to off-white

SMILES

O=C(C1=CC=C(C(F)=C1NC2=CC=C(I)C=C2F)F)NOC[C@H](O)CO

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Data Sheet (272 KB) SDS (644 KB) Handling Instructions (2659 KB)

References

[1]. Avolio E, et al. Cardiac pericyte reprogramming by MEK inhibition promotes arteriologenesis and angiogenesis of the ischemic heart. J Clin Invest. 2022 May 16;132(10):e152308. [Content Brief]

[2]. Suo N, et al. Inhibition of MAPK/ERK pathway promotes oligodendrocytes generation and recovery of demyelinating diseases. Glia. 2019 Jul;67(7):1320-1332. [Content Brief]

[3]. Ai Z, et al. Maintenance of Self-Renewal and Pluripotency in J1 Mouse Embryonic Stem Cells through Regulating Transcription Factor and MicroRNA Expression Induced by PD0325901. Stem Cells Int. 2016;2016:1792573. [Content Brief]

Mirdametinib Related Classifications

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass		Concentration		Volume		Molecular Weight *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)	×	Volume _(start)	=	Concentration _(final)	×	Volume _(final)
	×		=		×
C1		V1		C2		V2

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Mirdametinib (GMP)391210-10-9PD0325901 (GMP)PD325901 (GMP)MEKMitogen-activated protein kinase kinaseMAPKKMAP2KGMPPCOPCVSMCESCOLInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Product Name			Requested Quantity *
Applicant Name *			Salutation
Email Address *			Phone Number *
Department			Organization Name *
City			State
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Mirdametinib (Synonyms: PD0325901; PD325901)

Customer Review

Mirdametinib Related Antibodies

1 Publications Citing Use of MCE Mirdametinib

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All MEK Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Mirdametinib Related Antibodies

Mirdametinib Related Classifications

Molarity Calculator

Dilution Calculator

The molarity calculator equation

The dilution calculator equation

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report